Earnings summaries and quarterly performance for Pacira BioSciences.
Executive leadership at Pacira BioSciences.
Board of directors at Pacira BioSciences.
Research analysts who have asked questions during Pacira BioSciences earnings calls.
Hardik Parikh
JPMorgan Chase & Co.
3 questions for PCRX
Also covers: RPRX, VKTX
LS
Leszek Sulewski
Truist Securities
3 questions for PCRX
Also covers: AKBA, AMRX, ANIP +6 more
Gary Nachman
Raymond James
2 questions for PCRX
Also covers: ABBV, ACHV, ADMA +9 more
OL
Oren Livnat
H.C. Wainwright
2 questions for PCRX
Also covers: ANIP, AVDL, CARA +7 more
SB
Serge Belanger
Needham & Company
2 questions for PCRX
Also covers: AMPH, ARQT, BCRX +12 more
AN
Anish Nikhanj
RBC Capital Markets
1 question for PCRX
Also covers: APTO, CRMD, EXEL +6 more
David Amsellem
Piper Sandler Companies
1 question for PCRX
Also covers: ABBV, ALKS, AMGN +27 more
Denis Reznik
Raymond James
1 question for PCRX
Also covers: AQST, INMB, VERU
DM
Douglas Miehm
RBC Capital Markets
1 question for PCRX
Also covers: ACB, AUPH, BHC +2 more
Gregory Renza
RBC Capital Markets
1 question for PCRX
Also covers: ACAD, ADCT, AGIO +12 more
JG
John Gionco
Needham & Co.
1 question for PCRX
Also covers: AMPH, CYTK, TRVI
TW
Tejas Wein
Raymond James
1 question for PCRX
Also covers: FOLD
Recent press releases and 8-K filings for PCRX.
Pacira Highlights Strong 2025 Performance and Outlines 2026 Growth Catalysts
PCRX
Revenue Acceleration/Inflection
New Projects/Investments
Share Buyback
- Pacira reported unaudited sales of $726 million for the last year (2025) and experienced a 40%+ increase in its stock price between January 2nd and December 28th of that year.
- The company's 5x30 strategy targets double-digit top-line growth and a five-point margin expansion, with a guided margin of 80%-82% from a 76% baseline.
- The Exparel runway is solidified until 2039 due to a volume-limited settlement with Fresenius and Hengrui, supported by 21 patents.
- Strategic initiatives include partnerships with Johnson & Johnson MedTech and LG Chem, and a $150 million stock buyback that reduced outstanding shares to 41 million.
- Pacira expects three significant data readouts in 2026: Zilretta OA shoulder interim results, Iovera Spasticity in the first half, and PCRX201 Phase 2 Part A by year-end.
1 day ago
Pacira Reports Strong 2025 Performance and Outlines 2026 Pipeline Catalysts
PCRX
Revenue Acceleration/Inflection
New Projects/Investments
Share Buyback
- Pacira reported unaudited sales of $726 million for the past year and achieved a 40-plus% increase in its stock price between January 2nd and December 28th. The company is pursuing its 5x30 strategy with goals including double-digit top-line growth and a five-point margin expansion by 2030, guiding to 80%-82% margin.
- The company solidified its Exparel franchise by reaching a volume-limited settlement with Fresenius and Hengrui, providing visibility out to 2039, and strengthening its IP estate to 21 patents. Exparel also saw increased year-over-year volume growth, with Q3 at 9% and Q4 at 7%, driven by expanded commercial coverage reaching 102 million covered lives.
- Key pipeline data catalysts are anticipated in 2026, including interim readout for Zilretta OA of the shoulder, results for Iovera Spasticity in the first half, and PCRX201 Phase 2 Part A data by year-end.
- Pacira executed a $150 million stock buyback and formed significant partnerships with Johnson & Johnson MedTech for Zilretta and LG Chem for Exparel in the Asia-Pacific region.
1 day ago
Pacira Highlights 2025 Achievements and 2026 Growth Drivers at J.P. Morgan Conference
PCRX
Revenue Acceleration/Inflection
New Projects/Investments
Legal Proceedings
- Pacira reported unaudited sales of $726 million for the last year (2025) and experienced a 40+% increase in its stock price between January 2nd and December 28th, 2025.
- The company's 5x30 strategy has led to robust top-line growth and the highest historical margins, supported by a volume-limited settlement for EXPAREL providing visibility until 2039 and a strong IP estate of 21 patents.
- Pacira is entering a data-rich period with key pipeline readouts anticipated in 2026 for ZILRETTA (OA of the shoulder), iovera (Spasticity), and PCRX-201 (Phase II part A).
- Strategic partnerships, including with Johnson & Johnson Medical for ZILRETTA and LG Chem for EXPAREL in Asia-Pacific, are expanding market reach and contributing to growth.
- The NOPAIN legislation has driven market access, with 102 million covered lives by the end of 2025, leading to EXPAREL volume growth of 9% in Q3 2025 and 7% in Q4 2025.
1 day ago
Pacira Biosciences Reports Strong 2025 Revenue and Outlines 5x30 Growth Strategy
PCRX
Guidance Update
Share Buyback
New Projects/Investments
- Pacira Biosciences reported preliminary and unaudited revenue of $726 million for 2025 and projects $726 million in product revenue for 2026. The company also achieved +41% stock price growth from January 2 to December 28.
- The company is advancing its 5x30 growth strategy, aiming for gross margins of 80-82% in 2025 and >= 81% by 2030, supported by $150 million in stock repurchases in 2025 and a TTM Adjusted EBITDA of over $200 million.
- Key initiatives include expanding its clinical pipeline with 5 novel programs and establishing 5 partnerships, such as the EXPAREL regional distribution agreement with LG Chem.
- The NOPAIN Act has significantly expanded commercial coverage in 2025, contributing to 7% year-over-year EXPAREL volume growth in Q4 2025.
1 day ago
Pacira BioSciences Partners with LG Chem for EXPAREL Distribution
PCRX
Product Launch
New Projects/Investments
- Pacira BioSciences has entered into an agreement with LG Chem to expand patient access to EXPAREL® (bupivacaine liposome injectable suspension) in select Asian-Pacific markets.
- Under the terms of the partnership, LG Chem will be the exclusive distributor of EXPAREL in the region and plans to file for marketing authorizations in South Korea and Thailand within the next six months.
- Pacira will receive an undisclosed upfront payment, a transfer price, and tiered royalties on future commercial sales by LG Chem, while Pacira will manufacture EXPAREL.
- This collaboration is expected to significantly broaden the availability of EXPAREL in a region with unmet needs for long-acting postsurgical pain control and advances Pacira's 5x30 strategy.
3 days ago
Pacira BioSciences Reports Preliminary Q4 and Full-Year 2025 Revenues
PCRX
Earnings
Share Buyback
Revenue Acceleration/Inflection
- Pacira BioSciences reported preliminary, unaudited total revenue of $726.4 million for the full year ended December 31, 2025, compared with $701.0 million for the year ended December 31, 2024.
- EXPAREL net product sales for Q4 2025 were $155.8 million, driven by 7 percent volume growth, and full-year EXPAREL sales reached $575.1 million in 2025, with 6 percent volume growth.
- ZILRETTA net product sales were $33.0 million in Q4 2025 and $116.6 million for the full year 2025, while iovera° net product sales were $7.0 million in Q4 2025 and $24.2 million for the full year 2025.
- The company repurchased 2.0 million shares of its common stock for $50.0 million during the fourth quarter of 2025, and $150.0 million remained on its share repurchase authorization at December 31, 2025.
7 days ago
Pacira BioSciences Reports Preliminary Unaudited Q4 and Full-Year 2025 Revenues
PCRX
Earnings
Share Buyback
Revenue Acceleration/Inflection
- Pacira BioSciences reported preliminary, unaudited total revenue of $726.4 million for the full year ended December 31, 2025, an increase from $701.0 million in 2024.
- EXPAREL net product sales reached a record-high of $155.8 million in Q4 2025, driven by 7 percent volume growth, and $575.1 million for the full year 2025.
- The company repurchased 2.0 million shares of its common stock for $50.0 million during the fourth quarter of 2025, with $150.0 million remaining on its share repurchase authorization.
- CEO Frank D. Lee noted solid execution and meaningful progress advancing the company's 5x30 strategic priorities in 2025, positioning it for sustainable, long-term success.
7 days ago
Pacira BioSciences Discusses Product Portfolio, 5 by 30 Plan, and Pipeline at Conference
PCRX
Guidance Update
Share Buyback
New Projects/Investments
- Pacira BioSciences projects over $700 million in revenue and a couple hundred million in adjusted EBITDA for the current year, having also repurchased $100 million worth of stock over the last couple of quarters.
- The company's 5 by 30 Plan targets 10% CAGR top-line growth over the next five years, a 5% improvement in gross margin from 2024 levels, and aims for 3 million patients to benefit from its therapies by 2030.
- The No Pain Act has been implemented, providing separate reimbursement for Exparel at ASP + 6 in outpatient settings for CMS patients, which is expected to reinvigorate growth.
- Key pipeline developments include a registrational trial for ZILRETTA in OA of the shoulder with data expected mid-year, an interim readout for iovera in spasticity in the first half of next year, and the novel gene therapy PCRX-201 for OA of the knee, which has fully enrolled the first part of its Phase 2 trial and has RMAT designation.
Dec 2, 2025, 6:30 PM
Pacira BioSciences Provides Business and Pipeline Update
PCRX
Guidance Update
New Projects/Investments
Share Buyback
- Pacira BioSciences anticipates generating north of $700 million in revenue and a couple hundred million in adjusted EBITDA this year, alongside $100 million in stock repurchases over recent quarters.
- The company's "Five by 30 Plan" aims for 10% CAGR top-line growth over the next five years, a 5% improvement in gross margin compared to 2024 levels, and reaching 3 million patients by 2030.
- EXPAREL is benefiting from the No Pain Act, which provides separate reimbursement at ASP + six for non-opioid pain therapeutics in outpatient settings for CMS patients.
- Key pipeline updates include ZILRETTA's registrational trial for OA of the shoulder, which was expected to read out mid-2025, and the novel gene therapy PCRX-201's Phase II data readout anticipated approximately late 2026.
Dec 2, 2025, 6:30 PM
Pacira BioSciences Discusses Financial Outlook, Strategic Plan, and Pipeline Updates
PCRX
Guidance Update
New Projects/Investments
Revenue Acceleration/Inflection
- Pacira BioSciences expects to generate north of $700 million in revenue and a couple hundred million in adjusted EBITDA this year, with a capital allocation strategy that includes share repurchases.
- The company's "5 by 30 Plan" aims for 3 million patients benefiting from therapies by 2030, 10% CAGR top-line growth, and a 5% improvement in gross margin over the next five years compared to 2024 levels.
- Key pipeline developments include a registrational trial for Zilretta in OA shoulder with data expected mid-2025, an interim readout for iovera in spasticity in the first half of 2026, and phase 2 data for PCRX-201 (gene therapy for OA knee) around late 2026.
- The No Pain Act is expected to reinvigorate Exparel's growth by providing separate reimbursement at ASP + 6 for outpatient CMS patients.
Dec 2, 2025, 6:30 PM
Quarterly earnings call transcripts for Pacira BioSciences.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more